Last edition
News about "SEMABEST diabetes treatment"
MSN Laboratories Launches SEMABEST, India's First Semaglutide After Patent Expiry
MSN Laboratories launches SEMABEST, India’s first semaglutide post patent expiry, priced 50 percent lower than the innovator drug and available as a pre-filled pen for improved patient access.
SEMABEST Diabetes Treatment | 15/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members